Mega Lifesciences (MEGA) Aperçu de l'action
Mega Lifesciences Public Company Limited, avec ses filiales, fabrique et vend des compléments alimentaires, des produits pharmaceutiques sur ordonnance, des produits en vente libre, des produits à base de plantes, des vitamines et des biens de consommation à rotation rapide en Asie du Sud-Est et en Afrique subsaharienne. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 2/6 |
| Performances passées | 4/6 |
| Santé financière | 5/6 |
| Dividendes | 4/6 |
MEGA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mega Lifesciences Public Company Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ฿35.25 |
| Plus haut sur 52 semaines | ฿40.00 |
| Plus bas sur 52 semaines | ฿24.60 |
| Bêta | 0.32 |
| Variation sur 1 mois | -3.42% |
| Variation sur 3 mois | -1.40% |
| Variation sur 1 an | 39.60% |
| Variation sur 3 ans | -11.32% |
| Variation sur 5 ans | 0.71% |
| Évolution depuis l'introduction en bourse | 65.49% |
Nouvelles et mises à jour récentes
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Recent updates
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.Rendement pour les actionnaires
| MEGA | TH Pharmaceuticals | TH Marché | |
|---|---|---|---|
| 7D | -2.1% | -3.8% | 0.9% |
| 1Y | 39.6% | -2.6% | 40.3% |
Rendement vs Industrie: MEGA a dépassé le secteur TH Pharmaceuticals qui a rapporté -2.6 % au cours de l'année écoulée.
Rendement vs marché: MEGA correspond au marché TH qui a rapporté 40.3 % au cours de l'année écoulée.
Volatilité des prix
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TH Market | 10.5% |
| 10% least volatile stocks in TH Market | 2.2% |
Cours de l'action stable: MEGA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché TH.
Volatilité au fil du temps: La volatilité hebdomadaire de MEGA ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
Mega Lifesciences Public Company Limited, avec ses filiales, fabrique et vend des compléments alimentaires, des produits pharmaceutiques sur ordonnance, des produits en vente libre, des produits à base de plantes, des vitamines et des biens de consommation courante en Asie du Sud-Est et en Afrique subsaharienne. L'entreprise opère dans trois segments : Les marques, la distribution et la fabrication d'équipements d'origine (OEM). Elle fournit divers médicaments pour les allergies, la circulation sanguine et la mémoire, les os et les articulations, le foie et le système digestif, les diabétiques, les soins des yeux, du cœur et de la peau, la douleur, le sommeil, le bien-être, les plantes, la toux et le rhume, ainsi que des vitamines, des probiotiques, des produits de nutrition médicale et sportive, et des produits de soins pour les enfants, les hommes et les femmes.
Mega Lifesciences Public Company Limited Résumé des fondamentaux
| MEGA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ฿30.73b |
| Bénéfices(TTM) | ฿2.07b |
| Recettes(TTM) | ฿14.63b |
Le site MEGA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MEGA compte de résultat (TTM) | |
|---|---|
| Recettes | ฿14.63b |
| Coût des recettes | ฿6.94b |
| Marge brute | ฿7.69b |
| Autres dépenses | ฿5.62b |
| Les revenus | ฿2.07b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 13, 2026
| Résultat par action (EPS) | 2.37 |
| Marge brute | 52.55% |
| Marge bénéficiaire nette | 14.13% |
| Ratio dettes/capitaux propres | 4.6% |
Quelles ont été les performances à long terme de MEGA?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/06 14:52 |
| Cours de l'action en fin de journée | 2026/06/05 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Mega Lifesciences Public Company Limited est couverte par 16 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |